{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:45:20Z","timestamp":1773294320038,"version":"3.50.1"},"reference-count":34,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,5,1]]},"abstract":"<jats:p>Objective. To examine changes in antidepressant (ATD) prevalence and the sociodemographic and clinical correlates of ATD use among youths who are treated in community practice settings.<\/jats:p>\n               <jats:p>Methods. A retrospective study was undertaken using large data sets from 3 US sites. Outpatient prescription and clinical service records of youths who were aged 2 to 19 and enrolled in Midwestern Medicaid (MWM) and mid-Atlantic Medicaid (MAM) state programs and a group-model health maintenance organization (HMO) were organized into seven 1-year cross-sectional data sets from 1988 through 1994 to evaluate ATD utilization patterns.<\/jats:p>\n               <jats:p>Results. In 1994, ATD prevalence per 1000 youths was 19.10 (MWM), 17.78 (MAM), and 12.85 (HMO), which represented a consistent increase in prevalence from 1988\u20131994: 2.9-fold (MWM), 4.6-fold (MAM), and 3.6-fold (HMO). Despite the rapidly expanding use of selective serotonin reuptake inhibitors prescribed mainly for depression, more than half of ATD use in 1994 was still attributable to tricyclic antidepressants prescribed mainly for attention-deficit\/hyperactivity disorder. ATD prevalence was generally predominant among 10- to 14-year-old boys and among 15- to 19-year-old girls. In the Medicaid populations, 42% (MAM) and 72% (MWM) of ATD-treated youths had primary care services, whereas the bulk of the remainder had psychiatric services. Attention-deficit\/hyperactivity disorder followed by depression led the physician-reported primary care diagnoses associated with ATD use, whereas that diagnostic rank order was reversed for youths who received psychiatric services.<\/jats:p>\n               <jats:p>Conclusions. ATD treatments among youths substantially increased in the 1990s. This was generated primarily by primary care providers, and thus evaluations of the outcome of ATD treatment need to target primary care in addition to psychiatric providers. Longitudinal study designs are needed to evaluate the use of ATDs in youths in regard to the duration of treatment, combination medications, and the reasons for treatment.<\/jats:p>","DOI":"10.1542\/peds.109.5.721","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:17:55Z","timestamp":1092442675000},"page":"721-727","source":"Crossref","is-referenced-by-count":126,"title":["Rising Prevalence of Antidepressants Among US Youths"],"prefix":"10.1542","volume":"109","author":[{"given":"Julie Magno","family":"Zito","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Maryland, Baltimore, Maryland"},{"name":"School of Medicine, University of Maryland, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Safer","sequence":"additional","affiliation":[{"name":"School of Medicine, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"dosReis","sequence":"additional","affiliation":[{"name":"School of Public Health, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James F.","family":"Gardner","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Maryland, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Soeken","sequence":"additional","affiliation":[{"name":"School of Nursing, University of Maryland, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myde","family":"Boles","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Center for Health Research, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Lynch","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Center for Health Research, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2002,5,1]]},"reference":[{"key":"2021121006292566500_R1","doi-asserted-by":"crossref","unstructured":"Foote SM, Etheredge L. Increasing use of new prescription drugs: a case study. Health Aff (Millwood).2000;19:165\u2013170","DOI":"10.1377\/hlthaff.19.4.165"},{"key":"2021121006292566500_R2","doi-asserted-by":"crossref","unstructured":"Emslie GJ, Rush AJ, Weinberg WA. A double-blind, randomized placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry.1997;54:1031\u20131037","DOI":"10.1001\/archpsyc.1997.01830230069010"},{"key":"2021121006292566500_R3","doi-asserted-by":"crossref","unstructured":"Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry.2001;40:762\u2013772","DOI":"10.1097\/00004583-200107000-00010"},{"key":"2021121006292566500_R4","doi-asserted-by":"crossref","unstructured":"Zito JM, Safer DJ. Antidepressant treatment in children and adolescents: bridging the gap between efficacy and effectiveness. Curr Psychiatry Rep.2001;3:115\u2013125","DOI":"10.1007\/s11920-001-0008-z"},{"key":"2021121006292566500_R5","doi-asserted-by":"crossref","unstructured":"Olfson M, Marcus SC, Pincus HA, Zito JM, Thompson JW, Zarin DA. Antidepressant prescribing practices of outpatients psychiatrists. Arch Gen Psychiatry.1998;55:310\u2013316","DOI":"10.1001\/archpsyc.55.4.310"},{"key":"2021121006292566500_R6","unstructured":"Strauch B. Use of antidepression medicine for young patients has soared. New York Times.1997; Aug 10:1, 24"},{"key":"2021121006292566500_R7","doi-asserted-by":"crossref","unstructured":"Crowley M. Do kids need Prozac?Newsweek.1997; Oct 20: 73\u201374","DOI":"10.1016\/S1367-0484(97)80046-X"},{"key":"2021121006292566500_R8","unstructured":"Chua-Eoan H. Escaping from the darkness. Time.1999; May 31: 44\u201349"},{"key":"2021121006292566500_R9","doi-asserted-by":"crossref","unstructured":"Zito JM, Safer DJ. Sources of data for pharmacoepidemiological studies of child and adolescent psychiatric disorders. J Child Adolesc Psychopharmacol.1997;7:237\u2013253","DOI":"10.1089\/cap.1997.7.237"},{"key":"2021121006292566500_R10","doi-asserted-by":"crossref","unstructured":"Zito JM, Safer DJ, Riddle MA, Johnson RE, Speedie SM, Fox M. Prevalence variations in psychotropic treatment of children. J Child Adolesc Psychopharmacol.1998;8:99\u2013105","DOI":"10.1089\/cap.1998.8.99"},{"key":"2021121006292566500_R11","unstructured":"Peterson BD, West J, Tanielian TL, et al. Mental health practitioners and trainees. In: Mandersheid RW, Henderson MJ, eds. Mental Health, United States, 1998. Washington, DC;1998:214\u2013246. DHHS Publ. No. [SMA] 99-3285"},{"key":"2021121006292566500_R12","doi-asserted-by":"crossref","unstructured":"Kelleher KJ, Hohmann AA, Larson DB. Prescription of psychotropics to children in office-based practice. Am J Dis Child.1989;143:855\u2013859","DOI":"10.1001\/archpedi.1989.02150190105033"},{"key":"2021121006292566500_R13","doi-asserted-by":"crossref","unstructured":"Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA.2000;283:1025\u20131030","DOI":"10.1001\/jama.283.8.1025"},{"key":"2021121006292566500_R14","unstructured":"Khandker RK, Simoni-Wastila LJ. Differences in prescription drug utilization and expenditures between blacks and whites in the Georgia Medicaid population. Inquiry.1998;35:78\u201387"},{"key":"2021121006292566500_R15","doi-asserted-by":"crossref","unstructured":"Shatin D, Levin R, Ireys HT, Haller V. Health care utilization by children with chronic illnesses: a comparison of Medicaid and employer-insured managed care. Pediatrics.1998;102(4). Available at: http:\/\/www.pediatrics.org\/cgi\/content\/full\/102\/4\/e44","DOI":"10.1542\/peds.102.4.e44"},{"key":"2021121006292566500_R16","doi-asserted-by":"crossref","unstructured":"Buck JA. Utilization of Medicaid mental health services by non-disabled children and adolescents. Psychiatr Serv1997;48:65\u201370","DOI":"10.1176\/ps.48.1.65"},{"key":"2021121006292566500_R17","doi-asserted-by":"crossref","unstructured":"Pincus HA, Tanielian TL, Marcus SC, et al. Prescribing trends in psychotropic medications. JAMA.1998;279:526\u2013531","DOI":"10.1001\/jama.279.7.526"},{"key":"2021121006292566500_R18","unstructured":"Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R. Treatment of Attention-Deficit\/Hyperactivity Disorder. Evidence Report\/Technology Assessment No. 11. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ);1999:50. AHRQ Publ. No. 00-E005"},{"key":"2021121006292566500_R19","doi-asserted-by":"crossref","unstructured":"Ambrosini PJ. A review of pharmacotherapy of major depression in children and adolescents. Psychiatr Serv.2000;51:627\u2013633","DOI":"10.1176\/appi.ps.51.5.627"},{"key":"2021121006292566500_R20","doi-asserted-by":"crossref","unstructured":"Geller BG, Reising D, Leonard HL, Riddle MA, Walsh BT. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry.1999;38:513\u2013516","DOI":"10.1097\/00004583-199905000-00012"},{"key":"2021121006292566500_R21","doi-asserted-by":"crossref","unstructured":"Hazell P, O\u2019Connell D, Heathcote D, Robertson J, Henry D. Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. BMJ.1995;310:897\u2013901","DOI":"10.1136\/bmj.310.6984.897"},{"key":"2021121006292566500_R22","doi-asserted-by":"crossref","unstructured":"Rushton JL, Clark SJ, Freed GL. Pediatrician and family physician prescription of selective serotonin reuptake inhibitors. Pediatrics.2000;105:82\u201391","DOI":"10.1542\/peds.105.6.e82"},{"key":"2021121006292566500_R23","doi-asserted-by":"crossref","unstructured":"Kelleher KJ, McInerny TK, Gardner WP, Childs GE, Wasserman RC. Increasing identification of psychosocial problems: 1979\u20131996. Pediatrics.2000;105:1313\u20131321","DOI":"10.1542\/peds.105.6.1313"},{"key":"2021121006292566500_R24","doi-asserted-by":"crossref","unstructured":"Jensen PS, Bhatara VS, Vitiello B, Hoagwood K, Feil M, Burke LB. Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry.1999;38:557\u2013565","DOI":"10.1097\/00004583-199905000-00017"},{"key":"2021121006292566500_R25","unstructured":"Zito JM, Safer DJ, dosReis S, et al. Ten Year Prevalence Trends for Psychotropic Medication From Two Health Service Systems. Presented at the New Clinical Drug Evaluation Meeting; June 1\u20134,1999; Boca Raton, FL. Abstract"},{"key":"2021121006292566500_R26","unstructured":"Safer DJ, Zito JM. Pharmacoepidemiology of methylphenidate and other stimulants for the treatment of ADHD. In: Greenhill LL, Osman BB, eds. Ritalin: Theory and Practice. 2nd ed. Larchmont, NY: MA Liebert, Inc;2000:7\u201326"},{"key":"2021121006292566500_R27","doi-asserted-by":"crossref","unstructured":"Goodwin R, Gould MS, Blanco C, Olfson M. Prescription of psychotropic medications to youths in office-based practice. Psychiatr Serv.2001;52:1081\u20131087","DOI":"10.1176\/appi.ps.52.8.1081"},{"key":"2021121006292566500_R28","doi-asserted-by":"crossref","unstructured":"Bright RA, Avorn J, Everitt DE. Medicaid data as a resource for epidemiologic studies: strengths and limitations. J Clin Epidemiol.1989;42:937\u2013945","DOI":"10.1016\/0895-4356(89)90158-3"},{"key":"2021121006292566500_R29","doi-asserted-by":"crossref","unstructured":"Carson JL, Ray WA, Strom BL. Medicaid databases. In: Strom BL, ed. Pharmacoepidemiology. New York, NY: John Wiley & Sons;2000:307\u2013324","DOI":"10.1002\/0470842555.ch19"},{"key":"2021121006292566500_R30","unstructured":"Milin RP, Simeon J, Spenst BA. Double-Blind Study of Paroxetine in Adolescents With Unipolar Major Depression, #NR-67. Presented at the American Academy of Child and Adolescent Psychiatry Annual Meeting; October1999; Chicago, IL. Abstract"},{"key":"2021121006292566500_R31","doi-asserted-by":"crossref","unstructured":"Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry.1990;14:791\u2013795","DOI":"10.1016\/0278-5846(90)90050-Q"},{"key":"2021121006292566500_R32","doi-asserted-by":"crossref","unstructured":"Rushton JL, Whitmire JT. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992\u20131998. Arch Pediatr Adolesc Med.2001;155:560\u2013565","DOI":"10.1001\/archpedi.155.5.560"},{"key":"2021121006292566500_R33","unstructured":"Pliszka SR, Carlson CL, Swanson JM. ADHD With Comorbid Disorders. New York, NY: Guilford Press;1999:115"},{"key":"2021121006292566500_R34","doi-asserted-by":"crossref","unstructured":"Vitiello B. Psychopharmacology for young children: clinical needs and research opportunities. Pediatrics.2001;108:983\u2013989","DOI":"10.1542\/peds.108.4.983"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/5\/721\/1114899\/pe0502000721.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/109\/5\/721\/1114899\/pe0502000721.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T14:57:04Z","timestamp":1639148224000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/109\/5\/721\/64290\/Rising-Prevalence-of-Antidepressants-Among-US"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,1]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2002,5,1]]},"published-print":{"date-parts":[[2002,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.109.5.721","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,1]]}}}